Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment
for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary …

Background Venous thromboembolism is a frequent complication of COVID-19 infection.
Less than 50% of pulmonary embolism (PE) is associated with the evidence of deep venous …

Randomized controlled trials leading to the approval of apixaban and rivaroxaban for
venous thromboembolism (VTE) did not include patients with upper extremity deep vein …

Background The natural history of patients with hematologic cancer and venous
thromboembolism (VTE) has not been consistently evaluated. We aimed to compare the …

The implementation of long-term parenteral nutrition (PN) often requires the placement of
central venous access, a procedure that carries a considerable risk of catheter-related …

Background Upper extremity deep vein thrombosis (UEDVT) accounts for~ 10% of all cases
of DVT. In the most widely referenced general review of DVT, the American Academy of …

Background Limited data are available on the role of direct oral anticoagulants (DOACs) for
the treatment of upper extremities deep vein thrombosis (UEDVT). Objectives The aim of this …

Background Data on complications following upper extremity vein thrombosis (UEVT) are
limited and heterogeneous. Methods The aim of the study was to evaluate the pooled …